Management of Atraumatic Hand Pain with Flexion

Initial Treatment Approach

The European League Against Rheumatism (EULAR) recommends beginning with topical NSAIDs or capsaicin as first-line pharmacologic therapy combined with joint protection education and range-of-motion exercises for atraumatic hand pain with flexion, reserving oral acetaminophen (up to 4g/day) for inadequate response 1, 2
For patients with thumb base involvement, consider carpometacarpal osteoarthritis, which commonly presents with pain during flexion and gripping activities 1, 2
Multiple joint involvement should be assessed for nodal, erosive, or inflammatory osteoarthritis patterns 2

Joint protection education focusing on avoiding adverse mechanical factors during daily activities is recommended for all patients 1, 3
A structured exercise regimen including both range-of-motion and strengthening exercises should be implemented immediately for all patients 1, 3
Local heat application (paraffin wax or hot packs) before exercise sessions has strong expert support (77% recommendation) 1, 3

Topical NSAIDs or capsaicin are preferred initial pharmacologic treatments for mild-to-moderate pain, especially when few joints are affected (effect size 0.77 for pain relief, equivalent efficacy to oral NSAIDs without gastrointestinal risk) 4
Acetaminophen up to 4g/day is the oral analgesic of first choice due to superior safety profile (strength of recommendation 87/100) 1, 2, 3
Oral NSAIDs should be used at the lowest effective dose for the shortest duration with periodic reassessment 1, 2, 3

Thumb base OA may benefit from splinting (preferably full splint covering both thumb and wrist for superior pain relief, NNT=4 for functional improvement) 4
Lateral angulation or flexion deformity may require orthoses to prevent progression 1, 2
Painful inflammatory flares may be treated with intra-articular corticosteroid injection, particularly effective for trapeziometacarpal joint 1, 2

The number of joints affected should influence the choice between topical and systemic therapy, with fewer joints favoring topical therapy 4
The presence of inflammation may warrant earlier corticosteroid injection 1
Comorbidities should guide NSAID selection based on cardiovascular and gastrointestinal risk 1, 2
Functional impact should determine the pace of progression through treatment tiers, with severe disability warranting accelerated progression 2, 5